PT - JOURNAL ARTICLE AU - VIRGINIA G. KAKLAMANI AU - MAUREEN SADIM AU - YVONI KOUMANTAKI AU - PHEDON KAKLAMANIS AU - BORIS PASCHE TI - Role of Polymorphisms in Adamantiades-Behçet’s Disease AID - 10.3899/jrheum.080676 DP - 2008 Dec 01 TA - The Journal of Rheumatology PG - 2376--2378 VI - 35 IP - 12 4099 - http://www.jrheum.org/content/35/12/2376.short 4100 - http://www.jrheum.org/content/35/12/2376.full SO - J Rheumatol2008 Dec 01; 35 AB - Objective We previously showed that Adamantiades-Behçet’s disease (A-BD) is associated with a lower incidence of malignancy compared with the general population. Transforming growth factor-β (TGF-β) has been shown to play a role in cartilage regeneration and is increased in patients with A-BD. We also found 2 functional polymorphisms of the TGF-β pathway, TGFBR1*6A and TGFB1*CC, that are associated with risk of malignancy. We tested whether incidence of these polymorphisms would differ in patients with A-BD compared with healthy controls of similar age and geographic location. Methods We performed a case-control study including 139 cases and 128 controls from Greece. Cases and controls were genotyped for TGFBR1*6A and TGFB1*CC. Results We found that cases had lower incidence of TGFBR1*6A compared with controls (11.3% vs 13.3%, respectively). Also, the incidence of TGFB1*CC was lower in cases than controls (24.6% vs 27.0%, respectively). These differences were not statistically significant. Conclusion Although there is a suggestion that the lower incidence of TGFBR1*6A in A-BD patients may play a protective role against development of malignancy, larger studies would be needed to fully evaluate the role of TGF-β and its polymorphisms in A-BD.